PFKFB3 and cancer: To determine the contribution of PFKFB3 activity in the response to platinum, we performed drug combination screenings in a dose-response matrix across a panel of cancer cell lines using the PFKFB3 inhibitor KAN0438757 [25,38], hereafter referred to as PFKFB3i, given its inhibition of PFKFB3 enzymatic activity, proven target engagement, and isoenzyme selectivity [25].